SOPHiA Genetics SA Profit Margin

SOPHiA Genetics SA (SOPH) currently reports a profit margin of -93.86% as of June 2026. That compares with -105.32% in the prior-year period — up 10.9% year over year. That is below the Healthcare sector average of 13.71%. Use the charts on this page to explore SOPHiA Genetics SA's profit margin history and peer comparisons.

SOPHiA Genetics SA's profit margin increased from -105.32% to -93.86% — a 10.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SOPHiA Genetics SA's profit margin of -93.86% is lower than the Healthcare sector average of 13.71%. That is roughly 784.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but SOPHiA Genetics SA's current -93.86% should be judged against Healthcare norms (sector average: 13.71%) and against SOPH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -93.86%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.71%. From there, open related valuation or income-statement pages for SOPHiA Genetics SA, and consider following SOPH for alerts when major investors trade the stock.